Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences.
ATM
ATR
CHK1
DNA damage response
DNA-PK
LYMPHOMA
PARP
WEE1
Journal
Cancer treatment reviews
ISSN: 1532-1967
Titre abrégé: Cancer Treat Rev
Pays: Netherlands
ID NLM: 7502030
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
25
05
2020
revised:
09
08
2020
accepted:
11
08
2020
pubmed:
7
9
2020
medline:
15
12
2020
entrez:
6
9
2020
Statut:
ppublish
Résumé
The DNA damage response (DDR) is a well-coordinated cellular network activated by DNA damage. The unravelling of the key players in DDR, their specific inactivation in different tumor types and the synthesis of specific chemical inhibitors of DDR represent a new hot topic in cancer therapy. In this article, we will review the importance of DDR in lymphoma development and how this can be exploited therapeutically. Specifically, we will focus on CHK1, WEE1, ATR, DNA-PK and PARP inhibitors, for which preclinical data as single agents or in combination has been accumulating, fostering their clinical development. The few available clinical data on these inhibitors will also be discussed.
Identifiants
pubmed: 32892059
pii: S0305-7372(20)30128-6
doi: 10.1016/j.ctrv.2020.102090
pii:
doi:
Substances chimiques
Poly(ADP-ribose) Polymerase Inhibitors
0
Protein Kinase Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102090Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.